T1	Participants 94 101	syncope
T2	Participants 302 390	patients with syncope who are at intermediate risk for an adverse cardiovascular outcome
T3	Participants 759 850	One hundred three consecutive patients (53 women; mean age 64+/-17 years) entered the study
T4	Participants 1637 1663	intermediate-risk patients
